Anti-integrin therapy addresses pathophysiology; targets early point in pathogenic pathway.
To read the full article please visit Ophthalmology Times: “Novel DME treatment derives from multimodal activity”
Anti-integrin therapy addresses pathophysiology; targets early point in pathogenic pathway.
To read the full article please visit Ophthalmology Times: “Novel DME treatment derives from multimodal activity”